ClearPoint Neuro (CLPT): Q4 2025 Earnings Review
Yesterday, CLPT reported its Q4 and FY2025 results.
Earlier this month, I shared my updated thoughts following the AMT-130 news, but since then, there have been new developments.
I’ll start there before diving into the key takeaways from the Earnings Report.
AMT-130 Drama Update
When I last wrote about CLPT earlier this month, the stock had dropped more than 20% after uniQure released a regulatory update indicating the FDA had concluded that the Phase I/II data for AMT-130 were insufficient to support a marketing application, and that the agency was strongly recommending a prospective, randomized, double-blind, sham-controlled study.
Since then, a few important developments have taken place.
Dr. Vinay Prasad, the polarizing FDA official widely seen as one of the key obstacles for gene therapy approvals, including AMT-130, has announced he’s leaving the agency at the end of April. According to Bloomberg, there are indications the FDA had actually been leaning toward backing AMT-130, but that Prasad intervened to block it. A key U.S. senator has also launched an investigation into the FDA over its handling of rare disease drug denials, which adds political pressure on the agency to revisit its stance.
On the other side of the Atlantic, the UK has been considerably more receptive. The MHRA has published a formal case study on AMT-130, describing it as a potential breakthrough treatment for Huntington’s disease and highlighting how its scientific advice process helped enable the therapy’s development. This is an encouraging signal that regulatory momentum may be building outside the U.S., even as the American path remains uncertain.
None of this guarantees anything. But the landscape around AMT-130 is meaningfully less negative today than it was two weeks ago. The departure of Prasad, the political scrutiny on the FDA, and positive signals from the UK all suggest the door hasn’t closed on this therapy, it’s just taking longer to open than we hoped.
From my last update to today, the odds of getting good news over the next 12 months have definitely improved.
Thesis: Brief Recap
Nine months ago, I wrote a Deep Dive on CLPT.
I started a small position at $13.20/share, added more at $11.92, and again at around $15.70 following the first positive AMT-130 news. My average cost is $14.03/share, and I own a small position compared with my usual concentrated approach.
Here’s what I said in Q2 and Q3, which still applies today:
“For me, quarterly numbers aren’t the main yardstick for progress. What matters most is whether CLPT’s biopharma partners are advancing toward FDA-approved therapies that will depend on ClearPoint’s platform, not just the precision navigation hardware required for direct-to-brain delivery, but also the software, services, and infrastructure that make these procedures possible. The core question isn’t if we’ll reach an inflection point, but how close we are to it. CLPT doesn’t depend on a single partner or FDA decision, it stands to benefit from dozens of partners that could expand its TAM by 20x or more over the next few years.”
That remains the essence of the story. CLPT isn’t trying to discover the next breakthrough therapy. It’s building the standardized delivery ecosystem that ensures those therapies can actually reach patients.
And this is precisely why, as I’ve always said, the quarterly numbers aren’t particularly meaningful at this stage. The current TAM is still quite small, which makes it hard to expect dramatic financial progress from one year to the next. The real story plays out when breakthrough neurological therapies start reaching patients at scale, that’s when ClearPoint’s revenue model truly shifts. Until then, what matters is whether the right pieces are falling into place.
That said, I’ll walk through the quarterly results as usual, and at the end, I’ll share my updated thoughts on the thesis and what I’m doing with my position.
Financial Highlights
CLPT reported Q4 2025 revenue of $10.4M (vs. $10.05M est.), up 34% YoY.
Breaking down the three segments:
Biologics & Drug Delivery revenue grew ~23% YoY to $5.2M, driven by $1.1M in higher product revenue as multiple biopharma partners continued advancing their trials. This was partially offset by a modest $0.1M decline in service revenue. Notably, Q4 2025 marked the highest volume of clinical trial cases ever supported by CLPT’s team, an important leading indicator of future demand as more programs progress through the pipeline.
Neurosurgery Navigation & Therapy revenue came in at $4.7M, up ~62% YoY. The growth was driven by an expanded customer base and the initial contribution from the IRRAflow product line following the IRRAS acquisition completed in November 2025. This segment continues to benefit from both organic growth and incremental revenue from new offerings.
Capital Equipment & Software revenue was $0.5M, slightly down from $0.6M last year. This remains the least predictable segment on a quarterly basis, given the inherent lumpiness of system placements.
Gross margin was 62% for Q4 2025, up slightly YoY but down from 63% in Q3.
Operating expenses for Q4 were $13.4M, compared to $10.4M in Q4 2024, driven primarily by IRRAS integration costs and higher professional services fees.
Net loss per share was ($0.27), missing estimates by $0.07. EPS has been consistently disappointing relative to expectations throughout the year, which is worth acknowledging even if it doesn’t change the long-term picture.
As of YE2025, the company held $45.9M in cash and cash equivalents, compared to $20.1M at YE2024. The increase reflects $51.4M in net proceeds from notes payable and a small stock offering, plus $1.1M of cash acquired through the IRRAS acquisition, partially offset by $23.9M used in operating activities and $1.9M in taxes related to net share settlement of equity awards. It’s worth noting that operating cash outflows were notably higher than in 2024, largely due to the paydown of $8M in liabilities assumed from the IRRAS acquisition, a nonrecurring event that management explicitly flagged as unlikely to repeat.
FY2025:
For the full year, ClearPoint reported total revenues of $37M, an increase of ~18% YoY, including a modest contribution from IRRAS following the late-November acquisition.
Gross margin was 61%, in line with 2024.
Breaking down the annual segments:
Biologics & Drug Delivery: $19M, up 10% YoY, driven by higher product sales as partners advanced their development programs.
Neurosurgery Navigation & Therapy: $14.8M, including $1.2M in IRRAflow revenue, up 44% YoY, driven by the expanded installed base and the full market release of the PRISM Laser System and iCT solution.
Capital Equipment & Software: $3.1M, down 18% YoY.
R&D expenses were $13.9M for the year, up 12% from $12.4M in 2024.
Sales and marketing expenses were $16.5M, up 14% from $14.5M, largely due to headcount growth in the clinical team and IRRAS integration costs.
G&A expenses jumped 38% to $16.5M from $12.0M, primarily due to $1.4M in severance costs related to the IRRAS acquisition, $1M in higher professional services fees, and various other integration-related costs.
Overall, last year reflects a company continuing to invest in expanding its platform while awaiting the larger revenue inflection tied to therapy commercialization.
2026 Guidance:
Management provided full-year 2026 revenue guidance of $52M-$56M.
This is notably lower than the $54-60M range previously projected for the combined CLPT + IRRAS entity when the acquisition was announced, and it’s also slightly below the $47.25M that analysts had estimated for CLPT on a standalone basis before the IRRAS deal.
CEO Joe Burnett explained the revision on two grounds.
First, the FDA’s current posture on rare diseases. Following communications from the agency to at least two of CLPT’s biopharma partners, uniQure (AMT-130) and REGENXBIO (RGX-121), management has now removed all revenue associated with the potential commercial launch of those products from 2026 guidance entirely. Importantly, the CEO stressed that this doesn’t apply to the broader partner pipeline, where most programs were already planning to conduct Phase III sham-controlled studies. The FDA’s more rigorous stance on rare diseases doesn’t change the timelines for Parkinson’s disease, epilepsy, and other larger-market indications, where this type of study was always part of the plan.
Second, the IRRAS integration. Management has taken a more conservative stance on European revenue from IRRAflow, having decided to reset certain distributor relationships in Europe and start fresh where needed. If the situation improves in the second half of the year, he explicitly reserved the right to revise guidance upward.
Organic growth and IRRAS-derived growth are expected to be roughly balanced, with all four current revenue segments expected to grow double digits in 2026.
Operational Progress
As I’ve emphasized many times since I started covering this company, the thesis isn’t about CLPT’s current numbers, it’s about how well the company is positioned to benefit from the upcoming wave of breakthroughs in neurology.
Here’s an update from management:
Pillar 1: Pre-Commercial Biologics & Drug Delivery
The ClearPoint Advanced Laboratories (CAL) facility in California has now completed its first preclinical study for a sponsor in Q4 2025 and is already executing additional studies in Q1 2026. Full construction will not be complete until the grand opening planned for the second half of the year, but the facility is already operational for smaller studies and is on track to add full GLP capability soon.
The biologics and drug delivery team set a company record for clinical trial case volume in Q4 2025, the highest ever. This matters because it reflects genuine demand from biopharma partners advancing their programs, even before the financial inflection from commercialization arrives.
CLPT has more than 60 active biopharma partners, supports more than 25 active clinical trials, and has more than 10 partner programs accepted to some form of FDA expedited review across 8 different indications. If just 1% of the patients in those indications were treated annually, that would translate to ~20,000 procedures per year, and at current ASPs, would generate more than $250M in additional revenue for ClearPoint.
Joe Burnett also shared something interesting: a single large GLP study from the CAL facility could be worth $15-20M in revenue on its own, representing a potential step-change in the biologics segment in any given year.
Pillar 2: Neurosurgery Navigation & Robotics
The 3.x software platform has seen strong adoption, particularly at sites planning to use ClearPoint in both the MRI and the operating room under CT guidance. Early results from the limited market release were described as very positive, with advantages in accuracy, procedure time, radiation dose, and room turnover. Data from this early experience is expected to be submitted for publication later in 2026.
The CE Mark for the 3.x software has been successfully obtained under CLPT’s new European notified body, which management described as a meaningful step toward consolidating the global installed base onto a single software version. This simplifies training and ensures all worldwide customers have access to the latest features.
At the request of several pharma partners, CLPT has now initiated the PMDA regulatory process in Japan and expects to perform its first cell therapy clinical trial cases there in the second half of 2026.
The robotic navigation platform is also making development progress. Multiple product usability showcases with customers are planned for 2026, and the first preclinical studies using the ClearPoint robotic platform at the CAL facility are expected before year-end. Joe Burnett emphasized the unique competitive position this creates: no other company will have a single software platform capable of operating across MRI, intraoperative CT, and robotics.
Pillar 3: Laser Therapy & Access
The PRISM Laser Therapy System received FDA clearance for 1.5T MRI compatibility in 2025, effectively opening up the other half of the U.S. laser therapy market that was previously inaccessible. The first 1.5T sites have already been installed, with proposals in front of numerous additional centers.
In 2026, management expects to seek European approval for PRISM, submit the Harmony 1.0 software with numerous PRISM visualization features, and publish the first tumor clinical trial enabled by PRISM. This last point positions ClearPoint to expand beyond its traditional functional neurosurgery base and into neuro-oncology, a customer segment it has historically been less active in.
On the access side, CLPT’s drill partner adeor received FDA clearance this week for the Velocity Alpha MR conditional power drill, designed to reduce procedure times compared to the currently available hand twist drill. CLPT has begun a limited market release, prioritizing early drug delivery sites where multiple trajectories are often required, exactly the use case where the Velocity drill provides the most meaningful advantage.
Joe Burnett drew an explicit connection between the laser therapy workflow and the future of drug delivery: in both cases, there are multiple trajectories, a volumetric therapeutic dose, periprocedural catheter adjustments, and minimally invasive access points. Every laser procedure a hospital performs today is building familiarity with the workflow of drug delivery tomorrow.
Pillar 4: Neurocritical Management (IRRAflow)
This is a new pillar for ClearPoint, introduced via the IRRAS acquisition. The IRRAflow system enables active irrigation and controlled drainage of hemorrhage, toxins, and clots to therapeutically treat intracranial pathologies.
IRRAS had an existing revenue base of ~$8-9M annually prior to the acquisition. The biggest near-term change management has made involves the European commercial strategy, where CLPT is selectively resetting distributor relationships and starting fresh where they feel a clean break is warranted.
Beyond its established market, IRRAflow’s flexible dual-lumen catheter is now being offered as an additional tool within the broader ClearPoint ecosystem, something biopharma partners can test and consider at the CAL facility for drug delivery applications. This is a longer-duration infusion option that fills what the CEO described as a historic gap in CLPT’s portfolio.
The ARCH randomized clinical trial, which IRRAflow is supporting, is expected to read out data at some point in 2026. A positive result showing both patient improvement and economic benefits (shorter hospital stays, fewer complications) could accelerate market share gains significantly in this segment.
Management is targeting a 20% share of the ~$500M neurocritical care market. That alone would contribute ~$100M in revenue to CLPT’s long-term model.
The Broader Vision
Joe Burnett laid out a two-phase strategy for the company.
Phase 1 (Fast Forward): Penetrate the existing $1B combined market opportunity across the four pillars, achieve 20% market share, generate $200M in annual revenue, and reach cash breakeven and profitability, all without needing any commercial drug approvals.
Phase 2 (Essential Everywhere): Build a new market for commercial cell and gene therapy delivery alongside CLPT’s 60+ biopharma partners, targeting 20,000 annual CGT procedures and an additional $300M in annual revenue. Combined with Phase 1, this is a pathway to $500M in annual revenue.
Management’s target growth rate for the foreseeable future is 15-20%+ organically, which he described as consistent with capturing roughly 1.5-2% additional market share per year across each of the four pillars.
During the Q&A, Lake Street Capital asked about the most advanced near-term partner programs beyond uniQure. Joe Burnett noted BlueRock and Neurona as examples of programs investors should watch, but deferred to those companies’ own public communications on timing. He pointed investors to the new corporate presentation for a clearer view of the pipeline staging. He also emphasized that even Phase III trials generate meaningful procedure revenue for ClearPoint, with typical studies involving 60-120 patients. With potentially 10-15 studies running simultaneously, clinical trial volume alone could represent close to 1,000 patients annually beyond what’s already being counted.
B. Riley asked about the more than 10 partner programs now under FDA expedited review. The CEO noted there are now approximately 13 partners across 8 indications under expedited review, with Parkinson’s disease (4-5 partners) and drug-resistant epilepsy (MTLE) being the two largest by patient population. He underscored that the redundancy across partners in large indications like Parkinson’s is a meaningful risk mitigant: even if not all of them make it through, 1 or 2 approvals in a million-patient market could be transformative for CLPT.
Final Thoughts
I want to be honest here, in the same way I’ve always been.
Being fair to the team, they’ve been executing on pretty much everything within their control. The reality is that the current TAM is simply too small to generate meaningful financial progress without the revenue ramp that comes from the commercialization of breakthrough therapies. That has always been the central part of the thesis. It’s also something management can’t control. They can build the infrastructure, sign the partners, run the trials, and expand the installed base. But they can’t do anything to accelerate the development process or force the FDA to approve drugs.
That’s why, right now, the stock’s price action is more tied to AMT-130 developments than to anything in the quarterly results. The market understands this perfectly well. Growing at 15-20% per year from this base isn’t enough to move the needle or push the valuation higher. Until there’s a credible path to commercial procedure volume, the financial statements will continue to tell a modest story.
On that front, the AMT-130 situation has improved significantly since my last update. The departure of Vinay Prasad from the FDA, the political pressure building around rare disease denials, and the positive UK signals are all genuinely encouraging. I do think there’s a reasonable chance AMT-130 finds a path forward, whether in the U.S. eventually or through accelerated routes in the UK and Europe. But even in a best-case scenario, the financial impact for ClearPoint will take time to materialize. These things don’t move quickly.
And that’s really what I keep coming back to when weighing this against how much I believe in the company’s mission. I still believe in the long-term thesis. I still think ClearPoint could be worth multiples of today’s price in a few years if even a handful of these CNS therapies reach commercialization. But in the short term, this is increasingly looking like a potential opportunity cost situation that will require patience. The stock may well drift sideways for some time while we wait for the catalysts that actually move the needle financially, whether that’s from uniQure, BlueRock, Neurona, or something else entirely.
So, what am I doing? The same as I said after my recent update: holding. I’m not selling into what’s already been a significant drawdown, since I don’t think the current circumstances justify a lower price than this, but I’m not adding either. There are other opportunities in the market with clearer near-term setups, but given that this is already a small position, I don’t mind waiting for more clarity. As a concentrated investor, I could consider trimming or selling if I really needed the cash for another opportunity with a better risk-reward profile. Still, after seeing the potential impact of positive AMT-130 news and everything that has been improving the odds of that happening in the coming quarters, I don’t think it’s smart to do it now.
All in all, the thesis isn’t broken, but the timing of the path to commercial revenue will ultimately determine the stock’s performance.
As always, I’ll keep you updated if anything changes.
Disclaimer: As of this writing, M. V. Cunha holds a position in Clearpoint Neuro (CLPT) at $14.03/share.
Disclaimer: The views expressed in this article are solely my own and are based on my personal research and analysis. This content is for informational purposes only and should not be considered financial, investment, or legal advice. Always conduct your own research before making investment decisions.